Everpar Advisors
REGN icon

Everpar Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Everpar Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$472K Buy
622
+177
+40% +$134K 0.13% 154
2026
Q2 		$277K Sell
445
-98
-18% -$66.7K 0.08% 230
2026
Q1 		$420K Buy
543
+38
+8% +$29.1K 0.14% 152
2025
Q4 		$390K Sell
505
-112
-18% -$76.1K 0.14% 157
2025
Q3 		$347K Buy
617
+100
+19% +$56.5K 0.14% 174
2025
Q2 		$271K Buy
517
+71
+16% +$39.6K 0.12% 213
2025
Q1 		$283K Sell
446
-34
-7% -$23.4K 0.15% 193
2024
Q4 		$342K Sell
480
-113
-19% -$94.8K 0.17% 165
2024
Q3 		$623K Sell
593
-229
-28% -$255K 0.32% 78
2024
Q2 		$864K Buy
822
+133
+19% +$129K 0.43% 51
2024
Q1 		$663K Sell
689
-201
-23% -$191K 0.4% 71
2023
Q4 		$782K Buy
+890
New +$733K 0.36% 97

Other funds holding REGN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Everpar Advisors's REGN Position: Q3 2026 in Review

Everpar Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 40% in Q3 2026, buying an estimated $134K and bringing the position to 622 shares worth $472K. The position accounts for 0.13% of the portfolio, ranked #154.

Everpar Advisors first reported a position in REGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $864K in Q2 2024. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Everpar Advisors held 622 shares of Regeneron Pharmaceuticals worth $472K as of Q3 2026.
  • Everpar Advisors bought 177 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $134K.
  • Regeneron Pharmaceuticals made up 0.13% of Everpar Advisors's portfolio in Q3 2026, its #154 holding.
  • Everpar Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Everpar Advisors's Regeneron Pharmaceuticals position peaked at $864K in Q2 2024.
  • 1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Everpar Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.